At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
ocriplasmin +2 moredrug
Likely dose
ocriplasmin 75µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Sham-Injection Controlled, Double-Masked, Ascending-Dose, Dose-Range-Finding Trial of Microplasmin Intravitreal Injection for Non-Surgical Posterior Vitreous Detachment (PVD) Induction for Treatment of Vitreomacular Traction (VMT).
In Brief
A Phase 2 clinical trial evaluating ocriplasmin and Sham Comparator for Vitreomacular Traction. Completed, enrolled 60 participants across 4 sites in 2 countries.
Detailed Summary
A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with vitreomacular traction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitreomacular Traction
CountriesBelgium, Germany
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2007
First PostedFeb 2007
Primary CompletionJan 2009
Study CompletionFeb 2009
TodayJul 2026
First PostedFeb 15, 2007
Enrollment StartFeb 1, 2007
Primary CompletionJan 1, 2009
Study CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 19.4 years ago
Interventions
ocriplasmindrug
Intravitreal injection of ocriplasmin solution containing 75µg of ocriplasmin.
ocriplasmindrug
Intravitreal injection of ocriplasmin solution containing 125µg of ocriplasmin with up to 2 additional (open label) 125µg ocriplasmin injection at 1 month interval.
Sham Comparatordrug
Intravitreal sham injection